97 related articles for article (PubMed ID: 6526540)
1. Circadian bioavailability and some effects of propranolol in healthy subjects and in liver cirrhosis.
Semenowicz-Siuda K; Markiewicz A; Korczyńska-Wardecka J
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):653-8. PubMed ID: 6526540
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic and pharmacokinetic study of propranolol and atenolol in cirrhosis patients.
Rocher I; Decourt S; Leneveu A; Lebrec D; Rosier SP; Flouvat B
Int J Clin Pharmacol Ther Toxicol; 1985 Aug; 23(8):406-10. PubMed ID: 4044073
[TBL] [Abstract][Full Text] [Related]
3. [Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form].
Blanc M; Cales P; Grasset D; Ravaud A; Meskens C; Cotonat J; Pascal JP
Therapie; 1987; 42(2):187-91. PubMed ID: 3616995
[No Abstract] [Full Text] [Related]
4. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
5. [Strain-gauge plethysmographic measurement of the systemic bioavailability of oral nitroglycerin in liver cirrhosis].
Sabba' C; Pugliese D; Carbone P; Altomare E; Portincasa P; Buonamico P; Stufano N; D'Ercole M; Palasciano G; Albano O
Boll Soc Ital Biol Sper; 1983 Dec; 59(12):1825-31. PubMed ID: 6422959
[TBL] [Abstract][Full Text] [Related]
6. Value of propranolol-induced heart rate and blood pressure changes in predicting results of tilt testing.
Gielerak G; Kozłowski D; Dłuzniewska E; Roszczyk A; Cholewa M
Kardiol Pol; 2003 Feb; 58(2):98-108. PubMed ID: 14504635
[TBL] [Abstract][Full Text] [Related]
7. Enhanced bioavailability and decreased clearance of analgesics in patients with cirrhosis.
Neal EA; Meffin PJ; Gregory PB; Blaschke TF
Gastroenterology; 1979 Jul; 77(1):96-102. PubMed ID: 447033
[TBL] [Abstract][Full Text] [Related]
8. Circadian study of immunoreactive prolactin in patients with cirrhosis of the liver.
Tarquini B; Gheri R; Anichini P; Neri B; Buricchi L
Gastroenterology; 1977 Jul; 73(1):116-9. PubMed ID: 863182
[TBL] [Abstract][Full Text] [Related]
9. Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis.
Pasqualetti P; Casale R
Riv Eur Sci Med Farmacol; 1995; 17(4):125-9. PubMed ID: 8545565
[TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
11. Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study.
Breuel HP; Heine PR; Mück W; Niklaus H; Schmage N; Kuhlmann J
Int J Clin Pharmacol Ther; 1995 Feb; 33(2):103-8. PubMed ID: 7757308
[TBL] [Abstract][Full Text] [Related]
12. [Effect of portasystemic anastomoses in childhood on propranolol pharmacokinetics].
Cario WR; Glende M; Lampe D; Buchali K; Bürger K; Grossmann P; Huth M; Rüstow B; Zimmermann HB
Schweiz Med Wochenschr; 1981 Jul; 111(29):1088-93. PubMed ID: 7268362
[TBL] [Abstract][Full Text] [Related]
13. Influence of captopril, propranolol, and verapamil on arterial pulse wave velocity and other cardiovascular parameters in healthy volunteers.
Kähönen M; Ylitalo R; Kööbi T; Turjanmaa V; Ylitalo P
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):483-9. PubMed ID: 9760009
[TBL] [Abstract][Full Text] [Related]
14. Hepatic iron and zinc concentrations after portacaval shunting for nonalcoholic cirrhosis.
Adams PC; Bradley C; Frei JV
Hepatology; 1994 Jan; 19(1):101-5. PubMed ID: 8276345
[TBL] [Abstract][Full Text] [Related]
15. Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites.
Orloff MJ; Orloff MS; Orloff SL; Girard B
J Am Coll Surg; 1997 Jun; 184(6):557-70. PubMed ID: 9179111
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic variceal ligation plus propranolol vs. transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial.
Sauer P; Hansmann J; Richter GM; Stremmel W; Stiehl A
Endoscopy; 2002 Sep; 34(9):690-7. PubMed ID: 12195325
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetics of the beta-receptor blocker metipranolol in patients with liver cirrhosis (author's transl)].
Seyfried C; Ledermann H; Rennekamp H; L'age M; Abshagen U
Dtsch Med Wochenschr; 1982 Jan; 107(1):21-6. PubMed ID: 6120063
[TBL] [Abstract][Full Text] [Related]
18. Three decades of experience with emergency portacaval shunt for acutely bleeding esophageal varices in 400 unselected patients with cirrhosis of the liver.
Orloff MJ; Orloff MS; Orloff SL; Rambotti M; Girard B
J Am Coll Surg; 1995 Mar; 180(3):257-72. PubMed ID: 7874335
[TBL] [Abstract][Full Text] [Related]
19. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction.
Okabe H; Mizukami A; Taguchi M; Aiba T; Yasuhara M; Hashimoto Y
J Pharm Pharmacol; 2003 Apr; 55(4):479-86. PubMed ID: 12803769
[TBL] [Abstract][Full Text] [Related]
20. Clearance by the liver in cirrhosis. III. Propranolol uptake by the isolated perfused human liver.
Villeneuve JP; Dagenais M; Huet PM; Lapointe R; Roy A; Marleau D
Can J Physiol Pharmacol; 1996 Dec; 74(12):1327-32. PubMed ID: 9047043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
